

Qiagen and Incyte announce precision medicine collaboration

17 June 2025 | News

To develop companion diagnostics for patients with mutant CALR-expressing myeloproliferative neoplasms



Qiagen N.V., headquartered in Netherlands, and US-based Incyte have announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET).

Under the terms of the Master Collaboration Agreement with Incyte, Qiagen will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies.

The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of Qiagen's partnership with Illumina to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. Qiagen will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.

Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at Qiagen said, "This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in oncohematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes."